Pharma aggregator PharmEasy has handed over its digital duties to Performics.Convonix, part of Starcom India. The mandate involves all of paid media. The business was won following a highly competitive multi-agency pitch.
PharmEasy is a digital facilitator and helps patients connect with local pharmacy stores and diagnostic centres. It serves over 5 lakh families in India and is operational in seven cities, namely Mumbai, Delhi, Bengaluru, Kolkata, Pune, Jaipur and Ahmedabad. It has over 150 partner vendors.
Dharmil Sheth, Co-Founder of PharmEasy, said, âWe provide consumers with quality health products and services at a click of a button and give them the highest possible savings in the shortest possible time. Performics.Convonix is agile, ambitious, spirited and has a body of good solid work and rich insights on the pharma category. They are a great strategic partner to bring on board and their experience and expertise will give us maximum consumer connect across platforms and bang for the buck. While we reviewed several agencies, Performics.Convonix scored because of their strategic vision and thought-leadership on the category and the brand. Itâs wonderful to have them on board to further fuel our expansion plans.â
Sarfaraz Khimani, Co-CEO Performics.Convonix, said, âThis is a great win for us. PharmEasy is a brand that empowers consumers, and makes the best and most reliable health products and diagnostic services accessible to all. This is a brand built on trust, confidence, quality of service and excellence in product and we are pleased to partner with them in building the category.Â Healthcare is the largest utility vehicle and the digital healthcare industry in India is all set to boom, with a growing number of consumers opting to buy medicines the e-way. We look forward to making a significant difference to the PharmEasy brand. This will be a long and fruitful association.â
In the last financial year, PharmEasy has grown more than 200%, with a growth rate of 15% month on month. PharmEasy has recently raised a Series B funding of $16 million in a round led by Bessemer Venture Partners and Orios Venture Partners.